Literature DB >> 10195795

Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus.

M M McNeal1, M N Rae, R L Ward.   

Abstract

I.m. immunization of mice with inactivated rotavirus particles protects against subsequent infection. To optimize protection, the effects of different adjuvants (QS-21, QS-7, QUIL A, PCPP and RAS) with potential for human use were compared. Twenty-eight days after i.m. immunization with 20 microg of purified, UV/psoralen-inactivated murine rotavirus (EDIM), either with or without adjuvant, BALB/c mice were orally challenged with live EDIM and virus shedding was measured. All five adjuvants stimulated large (P < 0.001) increases in rotavirus antibody, but significant differences were found between adjuvants. The order of rotavirus IgG responses, i.e. no adjuvant < RAS < QS-7 < Quil A < QS-21 < PCPP, was the same as the order of protection except that QS-21 and PCPP were reversed. These results establish the importance of adjuvants during i.m. immunization with rotavirus and identify those with the greatest potential.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195795     DOI: 10.1016/s0264-410x(98)00359-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

Review 2.  Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.

Authors:  Akhilesh Kumar Shakya; Kutty Selva Nandakumar
Journal:  J R Soc Interface       Date:  2013-02       Impact factor: 4.118

3.  Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein.

Authors:  A H Choi; M Basu; M M McNeal; J D Clements; R L Ward
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

4.  Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs.

Authors:  L Yuan; C Iosef; M S Azevedo; Y Kim; Y Qian; A Geyer; T V Nguyen; K O Chang; L J Saif
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs.

Authors:  L Yuan; A Geyer; D C Hodgins; Z Fan; Y Qian; K O Chang; S E Crawford; V Parreño; L A Ward; M K Estes; M E Conner; L J Saif
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 6.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

7.  PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens.

Authors:  Nelson F Eng; Srinivas Garlapati; Volker Gerdts; Lorne A Babiuk; George K Mutwiri
Journal:  J Immune Based Ther Vaccines       Date:  2010-08-24

8.  Antibody repertoire analysis of mouse immunization protocols using microfluidics and molecular genomics.

Authors:  Michael A Asensio; Yoong Wearn Lim; Nicholas Wayham; Kacy Stadtmiller; Robert C Edgar; Jackson Leong; Renee Leong; Rena A Mizrahi; Matthew S Adams; Jan Fredrik Simons; Matthew J Spindler; David S Johnson; Adam S Adler
Journal:  MAbs       Date:  2019-03-21       Impact factor: 5.857

9.  Caspase-1 Dependent IL-1β Secretion and Antigen-Specific T-Cell Activation by the Novel Adjuvant, PCEP.

Authors:  Sunita Awate; Nelson F Eng; Volker Gerdts; Lorne A Babiuk; George Mutwiri
Journal:  Vaccines (Basel)       Date:  2014-06-26

10.  Psoralen Inactivation of Viruses: A Process for the Safe Manipulation of Viral Antigen and Nucleic Acid.

Authors:  Katherine Schneider; Loni Wronka-Edwards; Melissa Leggett-Embrey; Eric Walker; Peifang Sun; Brian Ondov; Travis H Wyman; M J Rosovitz; Sherry S Bohn; James Burans; Tadeusz Kochel
Journal:  Viruses       Date:  2015-11-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.